The British Journal of Psychiatry (2006) 189: 391-392. doi: 10.1192/bjp.bp.106.029983
© 2006 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by ADAMS, C. E.
Right arrow Articles by STROUP, T. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ADAMS, C. E.
Right arrow Articles by STROUP, T. S.

EDITORIAL

The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries{dagger}

CLIVE E. ADAMS

University of Leeds, Leeds, UK

PRATHAP THARYAN

Christian Medical College, Vellore, India

EVANDRO S. F. COUTINHO

Ozwaldo Cruz Foundation, Rio de Janeiro, Brazil

T. SCOTT STROUP

University of North Carolina, Carolina, Chapel Hill, North Carolina, USA

Correspondence: Professor Clive E. Adams, Co-ordinating Editor, Cochrane Schizophrenia Group, University of Leeds, 15 Hyde Terrace, Leeds LS2 9LT, UK. Tel: +44 (0)113 343 1965; fax: +44 (0)113 343 2723; email: ceadams{at}cochrane-sz.org

Declaration of interest T.S.S. has consulted for Janssen and consulted and spoken for Lilly and Pfizer; he is a principal investigator in a Schizophrenia Trials Network, sponsored by the National Institute of Mental Health, aiming to undertake pragmatic randomised trials.

See pp. 433–440, this issue.

Most people with schizophrenia live in low- and middle-income countries in which clinicians/policy makers are not the first targets of marketing. Because it is years after a drug is first launched that the full effects become known with confidence, the evidence upon which to base practice in low- and middle-income countries may be less biased than that in richer nations.


Related articles in BJP:

Highlights of this issue
SUKHWINDER S. SHERGILL
BJP 2006 189: 391-a17-391. [Full Text]  

Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia
ROBERT E. McCUE, RUBINA WAHEED, LEONEL URCUYO, GERALDINE ORENDAIN, MICHEL D. JOSEPH, RICHARD CHARLES, and SYED M. HASAN
BJP 2006 189: 433-440. [Abstract] [Full Text]  

PETER TYRER
BJP 2006 189: 478. [Full Text]  



This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
P. TYRER

The British Journal of Psychiatry, December 1, 2006; 189(6): 576 - 576.
[Full Text] [PDF]

eLetters:

Read all eLetters

The schizophrenia drug-treatment paradox
Vishal Agrawal
BJP Online, 23 Nov 2006 [Full text]